Home Home Home Inbox Home Search

Event

Effect of Nintedanib on Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis (IPF): Results from a Phase IIIb Trial [Board No. 215]

Location: Board no. 215
Session Type: RAPiD: Rapid Abstract Poster Discussion Session
Monday
May
21
2:15 PM
4:15 PM

Speaker(s)/Author(s)

Mitchell Kaye

M.D.
Minnesota Lung Center, Ltd.

Lawrence Homik

M.D.
Winnipeg Clinic

Craig S. Conoscenti

M.D.
Boehringer Ingelheim Pharmaceuticals Inc;Boehringer Ingelheim Pharmaceuticals Inc.

Jonathan Ilowite

M.D.
NYU Winthrop

Lisa Hood. Lancaster

M.D.
Vanderbilt Univ Medical Ctr;Vanderbilt University;Vanderbilt University Medical Center

Nesrin Mogulkoc

M.D.
Ege University Medical School;Istanbul Medikal Saglik Ve Yayinclinik Millet

Matthias Trampisch

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

View Abstract

Effect of Nintedanib on Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis (IPF): Results from a Phase IIIb Trial

Parent Sessions

  • B103 - ILD: MANAGEMENT
    05-21-2018 2:15 PM - 4:15 PM
    • Home Home Home Inbox Home Search